Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes? (Q51020788)

27 March 2018

editorial

0 references

title

Editorial. SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes? (English)

1 reference

27 March 2018

1 reference

Fabrice Bonnet

1

1 reference

27 March 2018

André J Scheen

series ordinal

2

1 reference

27 March 2018

publication date

1 December 2014

1 reference

27 March 2018

published in

Diabetes and Metabolism

1 reference

27 March 2018

volume

40

1 reference

27 March 2018

issue

6 Suppl 1

1 reference

27 March 2018

page(s)

S1-3

1 reference

27 March 2018

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

SGLT inhibitors in management of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

SGLT-2 inhibition in patients with kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

Composite endpoints in trials of type-2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2814%2972688-6

7 January 2021

10.1016/S1262-3636(14)72688-6

Identifiers

DOI

1 reference

27 March 2018

PubMed ID

25554065

1 reference

27 March 2018